Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
Miranda I MurrayMartin MarkowitzIan FrankRobert M GrantKenneth H MayerKrischan J HudsonBritt S StancilSusan L FordParul PatelAlex R RinehartWilliam R SpreenDavid A MargolisPublished in: HIV clinical trials (2018)
While Grade ≥2 injection-site pain was common, most participants reported overall satisfaction with and preference for cabotegravir LA, with few discontinuations due to injection intolerance. These findings support investigation of cabotegravir LA as an alternative to daily oral PrEP regimens.
Keyphrases
- men who have sex with men
- hiv positive
- hiv testing
- antiretroviral therapy
- ultrasound guided
- chronic pain
- hiv infected
- human immunodeficiency virus
- case report
- hepatitis c virus
- clinical trial
- pain management
- study protocol
- phase iii
- hiv aids
- physical activity
- phase ii
- hyaluronic acid
- spinal cord injury
- open label
- postoperative pain
- double blind